BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34266469)

  • 1. Transcriptome and genome evolution during HER2-amplified breast neoplasia.
    Lu P; Foley J; Zhu C; McNamara K; Sirinukunwattana K; Vennam S; Varma S; Fehri H; Srivastava A; Zhu S; Rittscher J; Mallick P; Curtis C; West R
    Breast Cancer Res; 2021 Jul; 23(1):73. PubMed ID: 34266469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.
    Van Bockstal M; Lambein K; Denys H; Braems G; Nuyts A; Van den Broecke R; Cocquyt V; De Wever O; Libbrecht L
    Virchows Arch; 2014 Sep; 465(3):275-89. PubMed ID: 24973889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case Report of
    Lee M; Lee J; Lee A; Kang J
    Int J Surg Pathol; 2023 Aug; 31(5):801-804. PubMed ID: 36437641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer.
    Coene ED; Schelfhout V; Winkler RA; Schelfhout AM; Van Roy N; Grooteclaes M; Speleman F; De Potter CR
    Virchows Arch; 1997 May; 430(5):365-72. PubMed ID: 9174626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
    Horimoto Y; Terao T; Tsutsumi Y; Tanabe M; Mogushi K; Hlaing MT; Sasaki R; Saeki H; Okazaki M; Sonoue H; Arakawa A; Saito M
    Am J Surg Pathol; 2019 Sep; 43(9):1221-1228. PubMed ID: 31192864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
    Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
    Seth RM; Burger AM; Kahn HJ
    Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
    Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
    Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
    Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
    Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
    Estévez LG; Suarez-Gauthier A; García E; Miró C; Calvo I; Fernández-Abad M; Herrero M; Marcos M; Márquez C; Lopez Ríos F; Perea S; Hidalgo M
    Breast Cancer Res; 2014 Sep; 16(4):R76. PubMed ID: 25186428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness.
    Glöckner S; Lehmann U; Wilke N; Kleeberger W; Länger F; Kreipe H
    Lab Invest; 2001 Apr; 81(4):565-71. PubMed ID: 11304576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.